You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameIpratropium bromide
Accession NumberDB00332  (APRD00537)
TypeSmall Molecule
GroupsApproved
DescriptionA muscarinic antagonist structurally related to atropine but often considered safer and more effective for inhalation use. It is used for various bronchial disorders, in rhinitis, and as an antiarrhythmic. [PubChem]
Structure
Thumb
Synonyms
(endo,syn)-(±)-3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-methyl-8-(1-methylethyl)-8-azoniabicyclo[3.2.1]octane bromide
3α-hydroxy-8-isopropyl-1αH,5αH-tropanium bromide (±)-tropate
8-Isopropylnoratropine methobromide
Bromure d'ipratropium
Bromuro de ipratropio
Ipratropii bromidum
Ipratropium bromide (anhydrous)
Ipratropium bromide anhydrous
Ipratropiumbromid
N-Isopropylnoratropinium bromomethylate
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
AtroventSpray, metered21 ug/1NasalBoehringer Ingelheim Pharmaceuticals, Inc.1996-01-01Not applicableUs
AtroventSolution250 mcgRespiratory (inhalation)Boehringer Ingelheim (Canada) Ltd Ltee1988-12-312007-10-11Canada
AtroventSpray, metered21 ug/1NasalPhysicians Total Care, Inc.2006-03-31Not applicableUs
AtroventSpray, metered42 ug/1NasalBoehringer Ingelheim Pharmaceuticals, Inc.1996-01-01Not applicableUs
AtroventSpray, metered42 ug/1NasalREMEDYREPACK INC.2014-05-28Not applicableUs
Atrovent HFAAerosol, metered20 mcgRespiratory (inhalation)Boehringer Ingelheim (Canada) Ltd Ltee2004-03-24Not applicableCanada
Atrovent HFAAerosol, metered17 ug/1Respiratory (inhalation)Boehringer Ingelheim Pharmaceuticals Inc.2005-05-01Not applicableUs
Atrovent HFAAerosol, metered17 ug/1Respiratory (inhalation)A S Medication Solutions2005-05-01Not applicableUs
Atrovent Nasal Aerosol 20mcg/aemAerosol20 mcgNasal; Respiratory (inhalation)Boehringer Ingelheim (Canada) Ltd Ltee1989-12-311999-08-09Canada
Atrovent Nasal Spray - 21mcg/aemAerosol, metered; Liquid21 mcgNasalBoehringer Ingelheim (Canada) Ltd Ltee1995-12-31Not applicableCanada
Atrovent Nasal Spray - 42mcg/aemAerosol, metered; Liquid42 mcgNasalBoehringer Ingelheim (Canada) Ltd Ltee1996-02-02Not applicableCanada
Atrovent Udv 125mcg/mlSolution125 mcgOral; Respiratory (inhalation)Boehringer Ingelheim (Canada) Ltd Ltee1993-12-312008-09-18Canada
Atrovent Udv Sol Inh 250mcg/mlSolution250 mcgRespiratory (inhalation)Boehringer Ingelheim (Canada) Ltd Ltee1992-12-312008-04-16Canada
AtroventhfaAerosol, metered17 ug/1Respiratory (inhalation)Physicians Total Care, Inc.2006-01-20Not applicableUs
Dom-ipratropiumLiquid0.3 mgNasal; Respiratory (inhalation)Dominion Pharmacal1999-09-15Not applicableCanada
Dom-ipratropium 125 Mcg/mlLiquid125 mcgRespiratory (inhalation)Dominion PharmacalNot applicableNot applicableCanada
Dom-ipratropium 250 Mcg/ml (1 Ml)Liquid250 mcgRespiratory (inhalation)Dominion PharmacalNot applicableNot applicableCanada
Dom-ipratropium 250 Mcg/ml (2 Ml)Liquid250 mcgRespiratory (inhalation)Dominion PharmacalNot applicableNot applicableCanada
Dom-ipratropium 250 Mcg/ml (20 Ml)Liquid250 mcgRespiratory (inhalation)Dominion PharmacalNot applicableNot applicableCanada
IpratropiumLiquid0.30 mgRespiratory (inhalation)Pharmel IncNot applicableNot applicableCanada
IpraventSolution0.03 %NasalAa Pharma Inc2002-12-03Not applicableCanada
IpraventSolution0.06 %NasalAa Pharma Inc2002-12-03Not applicableCanada
Mylan-ipratropium SolutionSolution0.25 mgRespiratory (inhalation)Mylan Pharmaceuticals Ulc1998-12-04Not applicableCanada
Novo-ipramide - Liq 0.25mg/mlSolution.25 mgRespiratory (inhalation)Novopharm Limited1996-12-312015-10-26Canada
Nu-ipratropium Plastic Ampules 250 Mcg/mlSolution250 mcgRespiratory (inhalation)Nu Pharm Inc1997-12-032012-09-04Canada
Penta-ipratropium BromideLiquid0.25 mgRespiratory (inhalation)Pentapharm Ltd.Not applicableNot applicableCanada
PHL-ipratropiumSolution125 mcgRespiratory (inhalation)Pharmel Inc1998-02-172016-10-25Canada
PHL-ipratropium - 20mlSolution250 mcgRespiratory (inhalation)Pharmel Inc1998-02-172009-10-26Canada
PHL-ipratropium - 1ml PolynebSolution250 mcgRespiratory (inhalation)Pharmel Inc1998-02-172016-10-25Canada
PHL-ipratropium - 2ml PolynebSolution250 mcgRespiratory (inhalation)Pharmel Inc1998-02-172016-10-25Canada
PMS-ipratropiumLiquid0.30 mgRespiratory (inhalation)Pharmascience Inc1999-04-15Not applicableCanada
PMS-ipratropiumSolution250 mcgRespiratory (inhalation)Pharmascience Inc1997-07-15Not applicableCanada
PMS-ipratropiumSolution125 mcgRespiratory (inhalation)Pharmascience Inc1997-10-29Not applicableCanada
PMS-ipratropium (2ml Unit Dose)Solution250 mcgRespiratory (inhalation)Pharmascience Inc1997-10-29Not applicableCanada
PMS-ipratropium (1ml Unit Dose)Solution250 mcgRespiratory (inhalation)Pharmascience Inc1997-10-29Not applicableCanada
Ratio-ipratropiumSpray, metered21 mcgNasalRatiopharm Inc Division Of Teva Canada Limited1999-09-282008-08-01Canada
Ratio-ipratropium Inhalation SolutionSolution250 mcgNasal; Respiratory (inhalation)Ratiopharm Inc Division Of Teva Canada Limited1994-12-312009-07-17Canada
Ratio-ipratropium UdvSolution250 mcgRespiratory (inhalation)Teva Canada Limited1995-12-31Not applicableCanada
Ratio-ipratropium UdvSolution125 mcgRespiratory (inhalation)Teva Canada Limited1997-12-04Not applicableCanada
Teva-ipratropium SterinebsSolution0.025 %Respiratory (inhalation)Teva Canada Limited1998-03-04Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-ipravent Solution - Inh 250mcg/mlSolution250 mcgRespiratory (inhalation)Apotex Inc1994-12-31Not applicableCanada
Apo-ipravent SterulesSolution0.025 %Respiratory (inhalation)Apotex Inc1998-07-09Not applicableCanada
Apo-ipravent SterulesSolution125 mcgRespiratory (inhalation)Apotex Inc2001-08-28Not applicableCanada
Ipratropium BromideSpray, metered42 ug/1NasalRebel Distributors Corp2003-03-31Not applicableUs
Ipratropium BromideSolution.5 mg/2.5mLRespiratory (inhalation)Cardinal Health2001-09-27Not applicableUs
Ipratropium BromideSolution.5 mg/2.5mLRespiratory (inhalation)Mylan Pharmaceuticals, Inc.2010-11-09Not applicableUs
Ipratropium BromideSolution.5 mg/2.5mLRespiratory (inhalation)Unit Dose Services2011-03-01Not applicableUs
Ipratropium BromideSolution.5 mg/2.5mLRespiratory (inhalation)Aidarex Pharmaceuticals LLC2011-02-01Not applicableUs
Ipratropium BromideSpray21 ug/1NasalWest Ward Pharmaceuticals Corp.2003-11-05Not applicableUs
Ipratropium BromideSolution.5 mg/2.5mLRespiratory (inhalation)Rebel Distributors Corp2005-05-09Not applicableUs
Ipratropium BromideSolution.5 mg/2.5mLRespiratory (inhalation)Preferred Pharmaceuticals, Inc2013-02-22Not applicableUs
Ipratropium BromideSpray, metered42 ug/1NasalREMEDYREPACK INC.2013-06-12Not applicableUs
Ipratropium BromideSolution.5 mg/2.5mLRespiratory (inhalation)Aurobindo Pharma Limited2016-10-27Not applicableUs
Ipratropium BromideSolution.5 mg/2.5mLRespiratory (inhalation)Cardinal Health1997-01-10Not applicableUs
Ipratropium BromideSolution.5 mg/2.5mLRespiratory (inhalation)Nephron Pharmaceuticals Corporation2001-09-27Not applicableUs
Ipratropium BromideSolution.5 mg/2.5mLRespiratory (inhalation)Physicians Total Care, Inc.1998-12-03Not applicableUs
Ipratropium BromideSpray42 ug/1NasalWest Ward Pharmaceuticals Corp.2003-11-05Not applicableUs
Ipratropium BromideSpray, metered42 ug/1NasalBausch & Lomb Incorporated2003-03-31Not applicableUs
Ipratropium BromideSolution.5 mg/2.5mLRespiratory (inhalation)Preferred Pharmaceuticals, Inc.2012-07-25Not applicableUs
Ipratropium BromideSolution.5 mg/2.5mLRespiratory (inhalation)REMEDYREPACK INC.2013-06-04Not applicableUs
Ipratropium BromideSolution.5 mg/2.5mLRespiratory (inhalation)Watson Laboratories, Inc.2011-03-01Not applicableUs
Ipratropium BromideSolution.5 mg/2.5mLRespiratory (inhalation)St Marys Medical Park Pharmacy2014-01-30Not applicableUs
Ipratropium BromideSpray, metered21 ug/1NasalBausch & Lomb Incorporated2003-03-31Not applicableUs
Ipratropium BromideSpray, metered42 ug/1NasalPhysicians Total Care, Inc.2004-04-12Not applicableUs
Ipratropium BromideSolution.5 mg/2.5mLRespiratory (inhalation)Ritedose Pharmaceuticals, LLC2011-02-01Not applicableUs
Ipratropium BromideSolution.5 mg/2.5mLRespiratory (inhalation)Rebel Distributors Corp2011-03-01Not applicableUs
Ipratropium BromideSpray42 ug/1NasalREMEDYREPACK INC.2013-07-16Not applicableUs
Ipratropium BromideSolution.5 mg/2.5mLRespiratory (inhalation)A S Medication Solutions2011-02-01Not applicableUs
Ipratropium BromideSolution.5 mg/2.5mLRespiratory (inhalation)Sandoz Inc.2011-09-01Not applicableUs
Ipratropium BromideSolution.5 mg/2.5mLRespiratory (inhalation)Proficient Rx LP2011-03-01Not applicableUs
Ipratropium BromideSolution.5 mg/2.5mLRespiratory (inhalation)Unit Dose Services2011-03-01Not applicableUs
Ipratropium BromideSpray, metered21 ug/1NasalPhysicians Total Care, Inc.2007-01-24Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AeroventTeva
ApoventApotex Inc.
AtronaseBoehringer Ingelheim
IpraxaIvax
IpventCipla Medpro
RhinoventBoehringer Ingelheim
RinatecBoehringer Ingelheim
RinovagosValeas
Brand mixtures
NameLabellerIngredients
Apo-salvent-ipravent SterulesApotex Inc
Combivent Inhalation AerosolBoehringer Ingelheim (Canada) Ltd Ltee
Combivent RespimatBoehringer Ingelheim (Canada) Ltd Ltee
Combivent UdvBoehringer Ingelheim (Canada) Ltd Ltee
DuonebMylan Specialty
Duovent UdvBoehringer Ingelheim (Canada) Ltd Ltee
IpramolIvax Pharmaceuticals Incorporated
Ipratropium Bromide and Albuterol SulfateTeva Pharmaceuticals USA Inc
Ratio-ipra Sal UdvTeva Canada Limited
Teva-combo SterinebsTeva Canada Limited
Salts
Name/CASStructureProperties
Ipratropium bromide hydrate
66985-17-9
Thumb
  • InChI Key: KEWHKYJURDBRMN-ZEODDXGYSA-M
  • Monoisotopic Mass: 429.151472
  • Average Mass: 430.383
DBSALT000208
Categories
UNIIVJV4X1P2Z1
CAS number22254-24-6
WeightAverage: 412.361
Monoisotopic: 411.140906478
Chemical FormulaC20H30BrNO3
InChI KeyLHLMOSXCXGLMMN-VVQPYUEFSA-M
InChI
InChI=1S/C20H30NO3.BrH/c1-14(2)21(3)16-9-10-17(21)12-18(11-16)24-20(23)19(13-22)15-7-5-4-6-8-15;/h4-8,14,16-19,22H,9-13H2,1-3H3;1H/q+1;/p-1/t16-,17+,18+,19?,21+;
IUPAC Name
(1R,3R,5S,8R)-3-[(3-hydroxy-2-phenylpropanoyl)oxy]-8-methyl-8-(propan-2-yl)-8-azabicyclo[3.2.1]octan-8-ium bromide
SMILES
[Br-].[H][C@]12CC[C@]([H])(C[C@@H](C1)OC(=O)C(CO)C1=CC=CC=C1)[N@+]2(C)C(C)C
Pharmacology
IndicationFor maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease, including chronic bronchitis and emphysema.
Structured Indications
PharmacodynamicsIpratropium bromide, a synthetic ammonium compound structurally similar to atropine, is used as a bronchodilator in the management of cholinergic-mediated bronchospasm associated with chronic obstructive pulmonary disease and in the treatment of rhinorrhea associated with the common cold or with allergic or nonallergic seasonal rhinitis.
Mechanism of actionIpratropium bromide is an anticholinergic agent. It blocks muscarinic cholinergic receptors, without specificity for subtypes, resulting in a decrease in the formation of cyclic guanosine monophosphate (cGMP). Most likely due to actions of cGMP on intracellular calcium, this results in decreased contractility of smooth muscle.
TargetKindPharmacological actionActionsOrganismUniProt ID
Muscarinic acetylcholine receptor M1Proteinyes
antagonist
HumanP11229 details
Muscarinic acetylcholine receptor M2Proteinyes
antagonist
HumanP08172 details
Muscarinic acetylcholine receptor M3Proteinyes
antagonist
HumanP20309 details
Related Articles
AbsorptionInhalation (local)-minimal; Nasal-rapid and minimal
Volume of distribution
  • 4.6 L/kg
Protein bindingMinimally (0 to 9% in vitro) bound to plasma albumin and α1-acid glycoproteins
Metabolism

Partially metabolized to at least 8 metabolites formed primarily via hydrolysis and conjugation. The main metabolites are N-isopropylnortropium methobromide, which is formed by enzymatic hydrolysis of the ester; α-phenylacrylic acid-N-isopropylnortropine-ester methobromide, which is formed by enzymatic loss of a water; and phenylacetic acid-N-isopropylnortropine-ester methobromide, which is formed by enzymatic loss of a CH3OH-group. These metabolites appear to be inactive.

SubstrateEnzymesProduct
Ipratropium bromide
Not Available
N-isopropylnortropium methobromideDetails
Ipratropium bromide
Not Available
Phenylacetic acid-N-isopropylnortropine-ester methobromideDetails
Route of eliminationPrimarily eliminated renally via active secretion.
Half life2-4 hours after administration orally, IV or by oral inhalation (radiolabeled ipratropium bromide assay measures parent drug and its metabolites). Using a radioreceptor assay that measures only unchanged ipratropium bromide, the initial distribution-phase half-life (t1/2 α) and terminal elimination-phase half-life (t1/2 β) were 0.07 and 1.6 hours, respectively, following a single 2 mg IV dose of the drug in healthy adults.
Clearance
  • 2.3 L/min (total clearance of active ingredient)
ToxicityLD50=1001mg/kg (orally in mice)
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with 1,10-Phenanthroline.Experimental
AbirateroneThe serum concentration of Ipratropium bromide can be increased when it is combined with Abiraterone.Approved
AclidiniumAclidinium may increase the anticholinergic activities of Ipratropium bromide.Approved
AlfentanilThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Alfentanil.Approved, Illicit
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Alphacetylmethadol.Experimental, Illicit
AmbenoniumThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Ambenonium.Approved
AmiodaroneThe metabolism of Ipratropium bromide can be decreased when combined with Amiodarone.Approved, Investigational
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Anisotropine Methylbromide.Approved
AprepitantThe serum concentration of Ipratropium bromide can be increased when it is combined with Aprepitant.Approved, Investigational
ArtemetherThe metabolism of Ipratropium bromide can be decreased when combined with Artemether.Approved
AtazanavirThe metabolism of Ipratropium bromide can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Ipratropium bromide can be decreased when combined with Atomoxetine.Approved
Atracurium besylateThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Atracurium besylate.Approved
AtropineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Atropine.Approved, Vet Approved
BenactyzineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Benactyzine.Withdrawn
BendroflumethiazideThe serum concentration of Bendroflumethiazide can be increased when it is combined with Ipratropium bromide.Approved
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Ipratropium bromide.Approved
BetaxololThe metabolism of Ipratropium bromide can be decreased when combined with Betaxolol.Approved
BexaroteneThe serum concentration of Ipratropium bromide can be decreased when it is combined with Bexarotene.Approved, Investigational
BezitramideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Bezitramide.Experimental, Illicit, Withdrawn
BiperidenThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Biperiden.Approved
BoceprevirThe metabolism of Ipratropium bromide can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Ipratropium bromide can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Ipratropium bromide can be decreased when it is combined with Bosentan.Approved, Investigational
Botulinum Toxin Type AIpratropium bromide may increase the anticholinergic activities of Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BIpratropium bromide may increase the anticholinergic activities of Botulinum Toxin Type B.Approved
BuprenorphineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Ipratropium bromide can be decreased when combined with Bupropion.Approved
ButorphanolThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Butorphanol.Approved, Illicit, Vet Approved
CarbamazepineThe metabolism of Ipratropium bromide can be increased when combined with Carbamazepine.Approved, Investigational
CarfentanilThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Carfentanil.Illicit, Vet Approved
CelecoxibThe metabolism of Ipratropium bromide can be decreased when combined with Celecoxib.Approved, Investigational
CeritinibThe serum concentration of Ipratropium bromide can be increased when it is combined with Ceritinib.Approved
ChloroquineThe metabolism of Ipratropium bromide can be decreased when combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe serum concentration of Chlorothiazide can be increased when it is combined with Ipratropium bromide.Approved, Vet Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Chlorphenoxamine.Withdrawn
ChlorpromazineThe metabolism of Ipratropium bromide can be decreased when combined with Chlorpromazine.Approved, Vet Approved
ChlorthalidoneThe serum concentration of Chlorthalidone can be increased when it is combined with Ipratropium bromide.Approved
CholecalciferolThe metabolism of Ipratropium bromide can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CimetidineThe metabolism of Ipratropium bromide can be decreased when combined with Cimetidine.Approved
CimetropiumIpratropium bromide may increase the anticholinergic activities of Cimetropium.Experimental
CinacalcetThe metabolism of Ipratropium bromide can be decreased when combined with Cinacalcet.Approved
CitalopramThe metabolism of Ipratropium bromide can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Ipratropium bromide can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Ipratropium bromide can be decreased when combined with Clemastine.Approved
ClobazamThe metabolism of Ipratropium bromide can be decreased when combined with Clobazam.Approved, Illicit
ClomipramineThe metabolism of Ipratropium bromide can be decreased when combined with Clomipramine.Approved, Vet Approved
ClotrimazoleThe metabolism of Ipratropium bromide can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe metabolism of Ipratropium bromide can be decreased when combined with Clozapine.Approved
CobicistatThe serum concentration of Ipratropium bromide can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Ipratropium bromide can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Codeine.Approved, Illicit
ConivaptanThe serum concentration of Ipratropium bromide can be increased when it is combined with Conivaptan.Approved, Investigational
CoumaphosThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Coumaphos.Vet Approved
CrizotinibThe metabolism of Ipratropium bromide can be decreased when combined with Crizotinib.Approved
CyclopentolateThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Cyclopentolate.Approved
CyclosporineThe metabolism of Ipratropium bromide can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Ipratropium bromide can be decreased when it is combined with Dabrafenib.Approved
DarifenacinThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Ipratropium bromide can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Ipratropium bromide can be increased when it is combined with Dasatinib.Approved, Investigational
DecamethoniumThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Decamethonium.Approved
DeferasiroxThe serum concentration of Ipratropium bromide can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Ipratropium bromide can be decreased when combined with Delavirdine.Approved
DemecariumThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Demecarium.Approved
DesipramineThe metabolism of Ipratropium bromide can be decreased when combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Desloratadine.Approved, Investigational
DexamethasoneThe serum concentration of Ipratropium bromide can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexetimideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Dexetimide.Withdrawn
DextromoramideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Dezocine.Approved
DichlorvosThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Dichlorvos.Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Dicyclomine.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe metabolism of Ipratropium bromide can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Ipratropium bromide can be decreased when combined with Diltiazem.Approved
DiphenhydramineThe metabolism of Ipratropium bromide can be decreased when combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Diphenoxylate.Approved, Illicit
DonepezilThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Donepezil.Approved
DoxycyclineThe metabolism of Ipratropium bromide can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with DPDPE.Investigational
DronabinolIpratropium bromide may increase the tachycardic activities of Dronabinol.Approved, Illicit
DronedaroneThe metabolism of Ipratropium bromide can be decreased when combined with Dronedarone.Approved
DuloxetineThe metabolism of Ipratropium bromide can be decreased when combined with Duloxetine.Approved
EchothiophateThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Echothiophate.Approved
EdrophoniumThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Edrophonium.Approved
EfavirenzThe serum concentration of Ipratropium bromide can be decreased when it is combined with Efavirenz.Approved, Investigational
EliglustatThe metabolism of Ipratropium bromide can be decreased when combined with Eliglustat.Approved
EluxadolineIpratropium bromide may increase the constipating activities of Eluxadoline.Approved
EnzalutamideThe serum concentration of Ipratropium bromide can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe metabolism of Ipratropium bromide can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Ipratropium bromide can be decreased when it is combined with Eslicarbazepine acetate.Approved
EthopropazineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Ethopropazine.Approved
EthylmorphineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Ethylmorphine.Approved, Illicit
EtorphineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Ipratropium bromide can be decreased when it is combined with Etravirine.Approved
FentanylThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenthionThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Fenthion.Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Fesoterodine.Approved
FluconazoleThe metabolism of Ipratropium bromide can be decreased when combined with Fluconazole.Approved
FluoxetineThe metabolism of Ipratropium bromide can be decreased when combined with Fluoxetine.Approved, Vet Approved
FluvoxamineThe metabolism of Ipratropium bromide can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Ipratropium bromide can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Ipratropium bromide can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Ipratropium bromide can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Ipratropium bromide can be increased when it is combined with Fusidic Acid.Approved
GalantamineThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Gallamine Triethiodide.Approved
Ginkgo bilobaThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Ginkgo biloba.Approved, Nutraceutical
Glucagon recombinantThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Glucagon recombinant.Approved
GlycopyrroniumIpratropium bromide may increase the anticholinergic activities of Glycopyrronium.Approved, Investigational, Vet Approved
HaloperidolThe metabolism of Ipratropium bromide can be decreased when combined with Haloperidol.Approved
HeroinThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Heroin.Approved, Illicit
HexamethoniumThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Hexamethonium.Experimental
HomatropineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Homatropine.Approved
Huperzine AThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Huperzine A.Investigational
HydrochlorothiazideThe serum concentration of Hydrochlorothiazide can be increased when it is combined with Ipratropium bromide.Approved, Vet Approved
HydrocodoneThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Hydrocodone.Approved, Illicit
HydroflumethiazideThe serum concentration of Hydroflumethiazide can be increased when it is combined with Ipratropium bromide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Hydromorphone.Approved, Illicit
HyoscyamineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Hyoscyamine.Approved
IdelalisibThe serum concentration of Ipratropium bromide can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Ipratropium bromide can be decreased when combined with Imatinib.Approved
ImipramineThe metabolism of Ipratropium bromide can be decreased when combined with Imipramine.Approved
IndapamideThe serum concentration of Indapamide can be increased when it is combined with Ipratropium bromide.Approved
IndinavirThe metabolism of Ipratropium bromide can be decreased when combined with Indinavir.Approved
IsavuconazoniumThe metabolism of Ipratropium bromide can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Isoflurophate.Approved, Withdrawn
IsoniazidThe metabolism of Ipratropium bromide can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Ipratropium bromide can be decreased when combined with Isradipine.Approved
ItoprideThe therapeutic efficacy of Itopride can be decreased when used in combination with Ipratropium bromide.Investigational
ItraconazoleThe metabolism of Ipratropium bromide can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Ipratropium bromide can be increased when it is combined with Ivacaftor.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Ketobemidone.Approved
KetoconazoleThe metabolism of Ipratropium bromide can be decreased when combined with Ketoconazole.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Levomethadyl Acetate.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Levorphanol.Approved
LofentanilThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Lofentanil.Illicit
LopinavirThe metabolism of Ipratropium bromide can be decreased when combined with Lopinavir.Approved
LorcaserinThe metabolism of Ipratropium bromide can be decreased when combined with Lorcaserin.Approved
LovastatinThe metabolism of Ipratropium bromide can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Loxapine.Approved
LuliconazoleThe serum concentration of Ipratropium bromide can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Ipratropium bromide can be increased when combined with Lumacaftor.Approved
LumefantrineThe metabolism of Ipratropium bromide can be decreased when combined with Lumefantrine.Approved
MalathionThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Malathion.Approved, Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Mecamylamine.Approved
MefloquineThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Mefloquine.Approved
MemantineThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Memantine.Approved, Investigational
MethadoneThe metabolism of Ipratropium bromide can be decreased when combined with Methadone.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Methadyl Acetate.Approved, Illicit
Methanesulfonyl FluorideThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Methanesulfonyl Fluoride.Investigational
MethanthelineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Methantheline.Approved
MethotrimeprazineThe metabolism of Ipratropium bromide can be decreased when combined with Methotrimeprazine.Approved
MethyclothiazideThe serum concentration of Methyclothiazide can be increased when it is combined with Ipratropium bromide.Approved
MetixeneThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Metixene.Approved
MetolazoneThe serum concentration of Metolazone can be increased when it is combined with Ipratropium bromide.Approved
MetoprololThe metabolism of Ipratropium bromide can be decreased when combined with Metoprolol.Approved, Investigational
MianserinMianserin may increase the anticholinergic activities of Ipratropium bromide.Approved
MifepristoneThe serum concentration of Ipratropium bromide can be increased when it is combined with Mifepristone.Approved, Investigational
MinaprineThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Minaprine.Approved
MirabegronThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Mirabegron.Approved
MitotaneThe serum concentration of Ipratropium bromide can be decreased when it is combined with Mitotane.Approved
ModafinilThe serum concentration of Ipratropium bromide can be decreased when it is combined with Modafinil.Approved, Investigational
MorphineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Morphine.Approved, Investigational
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with N-butylscopolammonium bromide.Vet Approved
NabiloneIpratropium bromide may increase the tachycardic activities of Nabilone.Approved, Investigational
NafcillinThe serum concentration of Ipratropium bromide can be decreased when it is combined with Nafcillin.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Nalbuphine.Approved
NefazodoneThe metabolism of Ipratropium bromide can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Ipratropium bromide can be decreased when combined with Nelfinavir.Approved
NeostigmineThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Ipratropium bromide can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Ipratropium bromide can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Ipratropium bromide can be decreased when combined with Nicardipine.Approved
NilotinibThe metabolism of Ipratropium bromide can be decreased when combined with Nilotinib.Approved, Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Normethadone.Approved, Illicit
NVA237The risk or severity of adverse effects can be increased when Ipratropium bromide is combined with NVA237.Investigational
OlaparibThe metabolism of Ipratropium bromide can be decreased when combined with Olaparib.Approved
OpiumThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Opium.Approved, Illicit
OrphenadrineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Orphenadrine.Approved
OsimertinibThe serum concentration of Ipratropium bromide can be increased when it is combined with Osimertinib.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Oxybutynin.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Ipratropium bromide.Approved
PalbociclibThe serum concentration of Ipratropium bromide can be increased when it is combined with Palbociclib.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Pancuronium.Approved
PanobinostatThe serum concentration of Ipratropium bromide can be increased when it is combined with Panobinostat.Approved, Investigational
ParoxetineThe metabolism of Ipratropium bromide can be decreased when combined with Paroxetine.Approved, Investigational
Peginterferon alfa-2bThe serum concentration of Ipratropium bromide can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentazocineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe metabolism of Ipratropium bromide can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Pentolinium.Approved
PethidineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Pethidine.Approved
PhenobarbitalThe metabolism of Ipratropium bromide can be increased when combined with Phenobarbital.Approved
PhenytoinThe metabolism of Ipratropium bromide can be increased when combined with Phenytoin.Approved, Vet Approved
PhysostigmineThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Physostigmine.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Pipecuronium.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Pirenzepine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Piritramide.Investigational
PolythiazideThe serum concentration of Polythiazide can be increased when it is combined with Ipratropium bromide.Approved
PosaconazoleThe metabolism of Ipratropium bromide can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
Potassium ChlorideIpratropium bromide may increase the ulcerogenic activities of Potassium Chloride.Approved, Withdrawn
PramlintidePramlintide may increase the anticholinergic activities of Ipratropium bromide.Approved, Investigational
PrimidoneThe metabolism of Ipratropium bromide can be increased when combined with Primidone.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Procyclidine.Approved
PromazineThe metabolism of Ipratropium bromide can be decreased when combined with Promazine.Approved, Vet Approved
PropanthelineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Propantheline.Approved
PropiverineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Propiverine.Investigational
PyridostigmineThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Pyridostigmine.Approved
QuinethazoneThe serum concentration of Quinethazone can be increased when it is combined with Ipratropium bromide.Approved
QuinidineThe metabolism of Ipratropium bromide can be decreased when combined with Quinidine.Approved
QuinineThe metabolism of Ipratropium bromide can be decreased when combined with Quinine.Approved
RamosetronIpratropium bromide may increase the constipating activities of Ramosetron.Approved
RanolazineThe metabolism of Ipratropium bromide can be decreased when combined with Ranolazine.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Remifentanil.Approved
RifabutinThe metabolism of Ipratropium bromide can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Ipratropium bromide can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Ipratropium bromide can be increased when combined with Rifapentine.Approved
RitonavirThe metabolism of Ipratropium bromide can be decreased when combined with Ritonavir.Approved, Investigational
RivastigmineThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Rivastigmine.Approved, Investigational
RolapitantThe metabolism of Ipratropium bromide can be decreased when combined with Rolapitant.Approved
RopiniroleThe metabolism of Ipratropium bromide can be decreased when combined with Ropinirole.Approved, Investigational
SaquinavirThe metabolism of Ipratropium bromide can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Scopolamine.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Scopolamine butylbromide.Approved
SecretinThe therapeutic efficacy of Secretin can be decreased when used in combination with Ipratropium bromide.Approved, Investigational
SertralineThe metabolism of Ipratropium bromide can be decreased when combined with Sertraline.Approved
SildenafilThe metabolism of Ipratropium bromide can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Ipratropium bromide can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Ipratropium bromide can be increased when it is combined with Simeprevir.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Solifenacin.Approved
St. John's WortThe serum concentration of Ipratropium bromide can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Ipratropium bromide can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Sufentanil.Approved, Investigational
SulfisoxazoleThe metabolism of Ipratropium bromide can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe therapeutic efficacy of Sulpiride can be decreased when used in combination with Ipratropium bromide.Approved
TacrineThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Tacrine.Withdrawn
TapentadolThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Tapentadol.Approved
TelaprevirThe metabolism of Ipratropium bromide can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Ipratropium bromide can be decreased when combined with Telithromycin.Approved
TerbinafineThe metabolism of Ipratropium bromide can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
ThioridazineThe metabolism of Ipratropium bromide can be decreased when combined with Thioridazine.Approved
TiclopidineThe metabolism of Ipratropium bromide can be decreased when combined with Ticlopidine.Approved
TiotropiumIpratropium bromide may increase the anticholinergic activities of Tiotropium.Approved
TipranavirThe metabolism of Ipratropium bromide can be decreased when combined with Tipranavir.Approved, Investigational
TocilizumabThe serum concentration of Ipratropium bromide can be decreased when it is combined with Tocilizumab.Approved
TolterodineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Tolterodine.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Tramadol.Approved, Investigational
TranylcypromineThe metabolism of Ipratropium bromide can be decreased when combined with Tranylcypromine.Approved
TrichlorfonThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Trichlorfon.Vet Approved
TrichlormethiazideThe serum concentration of Trichlormethiazide can be increased when it is combined with Ipratropium bromide.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Trihexyphenidyl.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Trimethaphan.Approved
TropicamideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Tropicamide.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Ipratropium bromide.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Tubocurarine.Approved
UmeclidiniumUmeclidinium may increase the anticholinergic activities of Ipratropium bromide.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Vecuronium.Approved
VenlafaxineThe metabolism of Ipratropium bromide can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Ipratropium bromide can be decreased when combined with Verapamil.Approved
VoriconazoleThe metabolism of Ipratropium bromide can be decreased when combined with Voriconazole.Approved, Investigational
ZiprasidoneThe metabolism of Ipratropium bromide can be decreased when combined with Ziprasidone.Approved
Food InteractionsNot Available
References
Synthesis Reference
  1. Abdine HH, Belala F, and Al-Badra AA. (2003). Ipratropium bromide: Methods of chemical and biochemical synthesis. In H.G. Brittain (Ed.). Profiles of drug substances, excipients and related methodology (pp. 85-99). Amsterdam, Netherlands: Elsevier Academic Press.
General References
  1. Yamatake Y, Sasagawa S, Yanaura S, Okamiya Y: [Antiallergic asthma effect of ipatropium bromide (Sch 1000) in dogs (author's transl)]. Nihon Yakurigaku Zasshi. 1977 Oct;73(7):785-91. [PubMed:145994 ]
External Links
ATC CodesR03BB01R03AL01R01AX03R03AL02
AHFS Codes
  • 12:08.08
PDB EntriesNot Available
FDA labelDownload (88.1 KB)
MSDSDownload (72.7 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.9425
Blood Brain Barrier+0.8883
Caco-2 permeable+0.6619
P-glycoprotein substrateSubstrate0.5085
P-glycoprotein inhibitor INon-inhibitor0.8489
P-glycoprotein inhibitor IINon-inhibitor0.5964
Renal organic cation transporterInhibitor0.6651
CYP450 2C9 substrateNon-substrate0.7214
CYP450 2D6 substrateNon-substrate0.7637
CYP450 3A4 substrateSubstrate0.6657
CYP450 1A2 substrateNon-inhibitor0.8412
CYP450 2C9 inhibitorNon-inhibitor0.9118
CYP450 2D6 inhibitorNon-inhibitor0.8915
CYP450 2C19 inhibitorNon-inhibitor0.8783
CYP450 3A4 inhibitorNon-inhibitor0.9396
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9528
Ames testNon AMES toxic0.7112
CarcinogenicityNon-carcinogens0.8979
BiodegradationReady biodegradable0.5154
Rat acute toxicity2.7983 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9596
hERG inhibition (predictor II)Inhibitor0.5879
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Boehringer ingelheim pharmaceuticals inc
  • Actavis mid atlantic llc
  • Bausch and lomb pharmaceuticals inc
  • Cobalt laboratories inc
  • Dey lp
  • Holopack international corp
  • Landela pharmaceutical
  • Nephron corp
  • Novex pharma
  • Pharmascience inc
  • Roxane laboratories inc
  • Teva parenteral medicines inc
  • Bausch and lomb inc
Packagers
Dosage forms
FormRouteStrength
SolutionRespiratory (inhalation)250 mcg
Spray, meteredNasal21 ug/1
Spray, meteredNasal42 ug/1
Aerosol, meteredRespiratory (inhalation)17 ug/1
Aerosol, meteredRespiratory (inhalation)20 mcg
AerosolNasal; Respiratory (inhalation)20 mcg
Aerosol, metered; liquidNasal21 mcg
Aerosol, metered; liquidNasal42 mcg
SolutionOral; Respiratory (inhalation)125 mcg
Aerosol, meteredOral; Respiratory (inhalation)
Spray, meteredRespiratory (inhalation)
LiquidNasal; Respiratory (inhalation)0.3 mg
LiquidRespiratory (inhalation)125 mcg
LiquidRespiratory (inhalation)250 mcg
SolutionOral; Respiratory (inhalation)
SolutionRespiratory (inhalation).5 mg/2.5mL
SprayNasal21 ug/1
SprayNasal42 ug/1
SolutionRespiratory (inhalation)
SolutionNasal0.03 %
SolutionNasal0.06 %
SolutionRespiratory (inhalation)0.25 mg
SolutionRespiratory (inhalation).25 mg
LiquidRespiratory (inhalation)0.25 mg
LiquidRespiratory (inhalation)0.30 mg
Spray, meteredNasal21 mcg
SolutionNasal; Respiratory (inhalation)250 mcg
SolutionRespiratory (inhalation)125 mcg
SolutionRespiratory (inhalation)0.025 %
Prices
Unit descriptionCostUnit
Atrovent HFA 17 mcg/act Aerosol 12.9 gm Inhaler143.59USD inhaler
Ipratropium bromide powder100.06USD g
Atrovent 0.03% Solution 30ml Nasal Spray96.95USD bottle
Atrovent 0.06% Solution 15ml Nasal Spray84.68USD bottle
Ipratropium Bromide 0.03% Solution 30ml Bottle53.82USD bottle
Ipratropium Bromide 0.06% Solution 15ml Bottle46.14USD bottle
Ipratropium Bromide 0.02% Solution Each Box Contains Twenty-Five 2.5ml Vials45.86USD box
Atrovent hfa inhaler11.89USD g
Atrovent 0.06% spray5.33USD ml
Atrovent 0.03% spray3.11USD ml
Ipratropium 0.06% spray2.96USD ml
Ipratropium 0.03% spray1.73USD ml
Atrovent 0.03 % Spray1.04USD ml
Apo-Ipravent 250 mcg/ml Solution0.58USD ml
Mylan-Ipratropium 250 mcg/ml Solution0.58USD ml
Novo-Ipramide 250 mcg/ml Solution0.58USD ml
Pms-Ipratropium 0.03 % Spray0.58USD ml
Pms-Ipratropium 250 mcg/ml Solution0.58USD ml
Atrovent Hfa 20 mcg/dose Metered Dose Aerosol0.1USD metered dose aerosol
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2151383 No2005-02-082013-12-06Canada
US5766573 No1992-11-282009-11-28Us
US5964416 No1996-10-042016-10-04Us
US6149054 No1996-12-192016-12-19Us
US6176442 No1996-10-042016-10-04Us
US6453795 No1996-12-052016-12-05Us
US6632842 No2001-12-282021-12-28Us
US6726124 No1996-10-042016-10-04Us
US6739333 No2000-05-262020-05-26Us
US6846413 No1998-08-282018-08-28Us
US6977042 No1998-08-282018-08-28Us
US6983743 No2000-05-262020-05-26Us
US6988496 No2000-02-232020-02-23Us
US7104470 No1996-10-042016-10-04Us
US7246615 No1996-05-312016-05-31Us
US7284474 No2004-08-262024-08-26Us
US7396341 No2006-10-102026-10-10Us
US7802568 No1999-02-262019-02-26Us
US7837235 No2008-03-132028-03-13Us
US7896264 No2005-05-262025-05-26Us
US7988001 No2001-08-042021-08-04Us
US8474447 No2010-01-172030-01-17Us
US8733341 No2009-12-162029-12-16Us
US9027967 No2007-03-312027-03-31Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point230-231.5U.S. Patent 3,505,337
water solubilityFreely solubleNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.000701 mg/mLALOGPS
logP0.21ALOGPS
logP-1.8ChemAxon
logS-5.8ALOGPS
pKa (Strongest Acidic)15.15ChemAxon
pKa (Strongest Basic)-2.7ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area46.53 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity105.9 m3·mol-1ChemAxon
Polarizability37.43 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylacetic acid derivatives. These are compounds containing a phenylacetic acid moiety, which consists of a phenyl group substituted at the second position by an acetic acid.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylacetic acid derivatives
Direct ParentPhenylacetic acid derivatives
Alternative Parents
Substituents
  • Phenylacetate
  • Tropane alkaloid
  • Beta-hydroxy acid
  • N-alkylpyrrolidine
  • Piperidine
  • Hydroxy acid
  • Quaternary ammonium salt
  • Pyrrolidine
  • Carboxylic acid ester
  • Azacycle
  • Organoheterocyclic compound
  • Monocarboxylic acid or derivatives
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organic bromide salt
  • Organic salt
  • Primary alcohol
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Organic cation
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Wellington K: Ipratropium bromide HFA. Treat Respir Med. 2005;4(3):215-20; discussion 221-2. [PubMed:15987237 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Wellington K: Ipratropium bromide HFA. Treat Respir Med. 2005;4(3):215-20; discussion 221-2. [PubMed:15987237 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Wellington K: Ipratropium bromide HFA. Treat Respir Med. 2005;4(3):215-20; discussion 221-2. [PubMed:15987237 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Keam SJ, Keating GM: Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD. Treat Respir Med. 2004;3(4):247-68. [PubMed:15350163 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Keam SJ, Keating GM: Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD. Treat Respir Med. 2004;3(4):247-68. [PubMed:15350163 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Symporter activity
Specific Function:
Sodium-ion dependent, high affinity carnitine transporter. Involved in the active cellular uptake of carnitine. Transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium. Also relative uptake activity ratio of carnitine to TEA is 11.3.
Gene Name:
SLC22A5
Uniprot ID:
O76082
Molecular Weight:
62751.08 Da
References
  1. Nakamura T, Nakanishi T, Haruta T, Shirasaka Y, Keogh JP, Tamai I: Transport of ipratropium, an anti-chronic obstructive pulmonary disease drug, is mediated by organic cation/carnitine transporters in human bronchial epithelial cells: implications for carrier-mediated pulmonary absorption. Mol Pharm. 2010 Feb 1;7(1):187-95. doi: 10.1021/mp900206j. [PubMed:20020740 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Symporter activity
Specific Function:
Sodium-ion dependent, low affinity carnitine transporter. Probably transports one sodium ion with one molecule of carnitine. Also transports organic cations such as tetraethylammonium (TEA) without the involvement of sodium. Relative uptake activity ratio of carnitine to TEA is 1.78. A key substrate of this transporter seems to be ergothioneine (ET).
Gene Name:
SLC22A4
Uniprot ID:
Q9H015
Molecular Weight:
62154.48 Da
References
  1. Nakamura T, Nakanishi T, Haruta T, Shirasaka Y, Keogh JP, Tamai I: Transport of ipratropium, an anti-chronic obstructive pulmonary disease drug, is mediated by organic cation/carnitine transporters in human bronchial epithelial cells: implications for carrier-mediated pulmonary absorption. Mol Pharm. 2010 Feb 1;7(1):187-95. doi: 10.1021/mp900206j. [PubMed:20020740 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 02, 2016 02:42